prof. MUDr. Michael Doubek, Ph.D.
Head of the research group, Michael Doubek Research Group: Genetic predisposition to hematologic disorders Neuroscience
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 2144, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 867
2018
-
Doporučení pro diagnostiku a léčbu chronické lymfocytární leukémie (CLL) - 2018
Transfuze a hematologie dnes, year: 2018, volume: 24, edition: 3
-
Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets
Year: 2018, type: Conference abstract
-
Epigenetic drug screen on resistant CLL cells reveals Aurora kinase inhibitors as enhancers of CD20 expression and sensitizers to treatment with CD20 monoclonal antibodies
Year: 2018, type: Conference abstract
-
Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression
Year: 2018, type: Conference abstract
-
Epigenetický screening buněk rezistentních k rituximabu odhalil možnou roli inhibitorů Aurora kináz v regulaci exprese CD20
Year: 2018, type: Conference abstract
-
Evolution of genomic abnormalities during CLL disease course is associated with telomere length changes
Year: 2018, type: Conference abstract
-
Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia
Haematologica/the hematology journal, year: 2018, volume: 103, edition: 2, DOI
-
Gene aberrations in adult patients with Ph-like ALL in the Czech Republic.
Year: 2018, type: Conference abstract
-
Gene aberrations in adult patients with Ph-negative ALL in the Czech Republic
Year: 2018, type: Conference abstract
-
Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience
Year: 2018, type: Conference abstract